Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Update

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 52,498 shares, a decrease of 36.1% from the February 12th total of 82,140 shares. Based on an average daily volume of 18,454 shares, the short-interest ratio is presently 2.8 days. Currently, 1.1% of the shares of the stock are sold short. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily volume of 18,454 shares, the short-interest ratio is presently 2.8 days.

Hedge Funds Weigh In On Evaxion A/S

A number of large investors have recently modified their holdings of the stock. SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S during the fourth quarter valued at approximately $72,000. Wesbanco Bank Inc. bought a new position in Evaxion A/S in the 4th quarter worth approximately $48,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S during the 4th quarter worth $38,000. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Evaxion A/S Price Performance

Evaxion A/S stock traded up $0.08 on Friday, reaching $4.26. The company’s stock had a trading volume of 86,851 shares, compared to its average volume of 26,935. Evaxion A/S has a twelve month low of $1.20 and a twelve month high of $12.15. The company has a market cap of $35.53 million, a price-to-earnings ratio of -3.23 and a beta of 0.28. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85. The business’s fifty day moving average price is $3.81 and its 200 day moving average price is $4.64.

Evaxion A/S (NASDAQ:EVAX) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.30 earnings per share (EPS) for the quarter. Equities analysts expect that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on EVAX shares. Maxim Group started coverage on Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 target price for the company. Wall Street Zen raised Evaxion A/S from a “hold” rating to a “buy” rating in a report on Saturday. Lake Street Capital lowered their target price on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, March 9th. JonesTrading assumed coverage on shares of Evaxion A/S in a research report on Tuesday, March 10th. They set a “buy” rating and a $10.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Evaxion A/S in a report on Monday, March 9th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Evaxion A/S has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.